CSF2 and cancer: Given that PD-1 inhibitors, radiotherapy, and GM-CSF (PRaG regimen) act specifically via distinct components of the cancer-immunity cycle, we aim to assess the clinical efficacy of triple-combination therapy in chemo-refractory patients with metastatic solid tumors.